Oligodendrocyte Progenitor Cell Culture From Human Brain

October 14, 2020 updated by: Rajavithi Hospital

Phase 1: Oligodendrocyte Progenitor Cell Culture From Human Brain

Recent developments in the understanding of stem- and progenitor cell differentiation raises hopes that brain damage in chronic neurological diseases may become repaired by systemic or focal transplantation of such cells. Clinical trials of stem- or progenitor cell transplantation in multiple sclerosis are currently premature. The researchers developed a protocol for human oligodendrocyte progenitor cell culture from human brain for the treatment of demyelinating disease.

Study Overview

Detailed Description

Oligodendrocyte progenitor cell line were cultures and will be transplanted into the patient with Multiple sclerosis.

Study Type

Interventional

Enrollment (Actual)

5

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Bangkok, Thailand, 10400
        • Assistant Professor Subsai Kongsaengdao

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Male or female 20-65 years of age
  • Informed consent
  • Has elective craniotomy surgery

Exclusion Criteria:

  • HIV, hepatitis, and other central nervous system (CNS) infections
  • Dementia, Alzheimer disease, and neurodegenerative disease

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: A
Progenitor cells from the patinets with Craniotomy with V-P Shunt or ventriculostomy will be collected and cultured.
Oligodendrocyte progenitor cell culture protocol of Rajavithi Hospital will be apply
Other Names:
  • Rajavithi Oligodendrocyte progenitor cell culture protocol

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Number of oligodendrocyte progenitor cell differentiation
Time Frame: one month
one month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Subsai Kongsaengdao, M.D., Division of Neurology, Department of Medicine, Rajavithi Hospital : Thailand

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 1, 2007

Primary Completion (Actual)

December 1, 2010

Study Completion (Actual)

December 1, 2010

Study Registration Dates

First Submitted

January 25, 2006

First Submitted That Met QC Criteria

January 26, 2006

First Posted (Estimate)

January 27, 2006

Study Record Updates

Last Update Posted (Actual)

October 19, 2020

Last Update Submitted That Met QC Criteria

October 14, 2020

Last Verified

October 1, 2020

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • RH-CMR-003
  • RVH-CMR-003 grant

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Demyelinating Diseases

Clinical Trials on Oligodendrocyte progenitor cell culture/craniotomy

3
Subscribe